Hemolytic uremic syndrome; pathogenesis, treatment, and outcome.
about
Shiga toxin 2 targets the murine renal collecting duct epitheliumDo the A subunits contribute to the differences in the toxicity of Shiga toxin 1 and Shiga toxin 2?Atypical hemolytic uremic syndrome: from diagnosis to treatmentClinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review.Haemolytic uraemic syndrome in children admitted to a rural district hospital in Kenya.Hemolytic uremic syndrome: pathogenesis and update of interventions.Therapeutic apheresis in the treatment of hemolytic uremic syndrome in view of pathophysiological aspects.Gastrointestinal dysfunction following hemolytic uremic syndrome.Clinical aspects of a nationwide epidemic of severe haemolytic uremic syndrome (HUS) in children.Common variable immunodeficiency complicated with hemolytic uremic syndromeMultifaceted hemolytic uremic syndrome in pediatrics.Secondary, profound, sensorineural hearing loss after recovery from haemolytic uraemic syndrome due to enterohaemorrhagic Escherichia coli, and subsequent cochlear implantation, in two Japanese children.Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome.The A1 Subunit of Shiga Toxin 2 Has Higher Affinity for Ribosomes and Higher Catalytic Activity than the A1 Subunit of Shiga Toxin 1.Haemolytic uraemic syndrome with peripheral gangrene and Kawasaki disease in a 15-month-old child.Evaluation of Fab and F(ab')2 fragments and isotype variants of a recombinant human monoclonal antibody against Shiga toxin 2.Salmonella enterica serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli.Identification of amino acids critical for the cytotoxicity of Shiga toxin 1 and 2 in Saccharomyces cerevisiae.Shiga toxin 1 is more dependent on the P proteins of the ribosomal stalk for depurination activity than Shiga toxin 2Diarrhea-associated hemolytic uremic syndrome in southern Alberta: A long-term single-centre experience.Decreased ER-associated degradation of alpha-TCR induced by Grp78 depletion with the SubAB cytotoxin.Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteersConserved Arginines at the P-Protein Stalk Binding Site and the Active Site Are Critical for Ribosome Interactions of Shiga Toxins but Do Not Contribute to Differences in the Affinity of the A1 Subunits for the Ribosome.Ricin uses arginine 235 as an anchor residue to bind to P-proteins of the ribosomal stalk.Latrunculin B facilitates Shiga toxin 1 transcellular transcytosis across T84 intestinal epithelial cells.Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential.A case of lethal enteroviral haemolytic uraemic syndrome?Atypical hemolytic-uremic syndrome (HUS) with recovery after a long-lasting anuria: a case report.The Per Case and Total Annual Costs of Foodborne Illness in the United States.A novel vehicle for transmission of Escherichia coli O157:H7 to humans: multistate outbreak of E. coli O157:H7 infections associated with consumption of ready-to-bake commercial prepackaged cookie dough--United States, 2009.Renal Recovery Years After Initial Diagnosis of Hemolytic Uremic Syndrome.Haemolytic-uremic syndrome due to infection with adenovirus: A case report and literature review.Validation of time and temperature values as critical limits for the control of Escherichia coli O157:H7 during the production of fresh ground beef.Functional Assays for Measuring the Catalytic Activity of Ribosome Inactivating Proteins.
P2860
Q24652310-96173B50-BA68-4C47-A5AA-ADAFE8085E1BQ26858938-25AD3E70-D078-488D-BAF0-152A69F74C50Q27023137-B2B7AEA6-D908-43C6-AFC0-7CE147E2ECDEQ33377495-C8E0D68C-9B1E-4408-BCDE-100C8988DC4AQ33380374-A740465B-AA0B-473F-A692-5E037FE27F3EQ33385809-21AA9BFF-8A71-4667-8E5E-E9AD328C38EDQ33393870-85419F64-6869-4F34-9A30-881A055F915EQ33395266-8B06ACFE-F1A0-4F4E-8B3C-84A505239201Q33396410-C407F985-7841-4E25-B235-6A908260900CQ33398023-D4E63D24-7920-4CF3-9D32-F1C989A249DCQ33405452-99AD7CBE-0DB0-4606-A054-1863E8442968Q33405856-748E1F2A-C5DA-4008-B64E-42608CC32454Q33415691-42C77E33-842A-4457-BD5B-8C5E3E7B63F1Q33426867-F03B03D8-67AE-4F0B-B48F-F3EF00A256D6Q33429070-368132A8-0B5D-4D93-BB61-A1EF409DC7E3Q33675818-EABEB557-0CE4-4CEF-BC1F-73DFA55144F0Q33768681-7FBC54D3-5110-4CE2-9739-49A8D3CBD6B1Q34663367-62302386-CE6A-46AC-898E-A1E5CBF990FAQ35501790-8E126170-22DA-4CD8-9903-1F5FBA5E438FQ35893773-F75C62A9-70C4-4577-8FC2-5DCE4D280E70Q36973217-DD7D7620-876E-400C-9DE0-D090055C020AQ37247682-1D88B238-3A26-42FF-BB04-C7A587D1FD11Q37424949-98098F12-0BB8-425C-A6CA-2C42744F5289Q37660963-26CAB014-F317-4955-9C1D-961C959329E0Q40002237-DB2F7A1E-1571-4C56-8ED7-C989ABA292E8Q40075347-BE32D85D-8748-4A4D-9E2B-FF0A2453FD5BQ40321271-4523ACB6-F67A-4290-8E90-F8397212CA58Q42108749-CF633920-72E6-4AED-AE1F-19C0C8663BF5Q42175709-72E04599-EA41-42B7-8510-F9D4A228BE7AQ43230569-4395EFE7-CA61-4B3C-947B-F0798A5CC80DQ49987283-5C4D6C8D-EFEA-4385-AFEB-57A5A34C354CQ50003267-352808DF-E2DC-4C02-8D75-8EE92E60AFA4Q54457285-57790D42-FD79-410D-93F5-0DDC94BF0CE5Q55515121-0AA06599-92B2-407B-B184-FDDE921A7783
P2860
Hemolytic uremic syndrome; pathogenesis, treatment, and outcome.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Hemolytic uremic syndrome; pathogenesis, treatment, and outcome.
@ast
Hemolytic uremic syndrome; pathogenesis, treatment, and outcome.
@en
type
label
Hemolytic uremic syndrome; pathogenesis, treatment, and outcome.
@ast
Hemolytic uremic syndrome; pathogenesis, treatment, and outcome.
@en
prefLabel
Hemolytic uremic syndrome; pathogenesis, treatment, and outcome.
@ast
Hemolytic uremic syndrome; pathogenesis, treatment, and outcome.
@en
P1476
Hemolytic uremic syndrome; pathogenesis, treatment, and outcome.
@en
P2093
Richard Siegler
Robert Oakes
P304
P356
10.1097/01.MOP.0000152997.66070.E9
P577
2005-04-01T00:00:00Z